These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11811390)

  • 1. Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors.
    Lüscher TF; Spieker LE; Noll G; Cosentino F
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S3-11. PubMed ID: 11811390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease?
    Ruschitzka FT; Lüscher TF
    Am Heart J; 1997 Aug; 134(2 Pt 2):S31-47. PubMed ID: 9313622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
    Gupta S; Wright HM
    Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide- and cyclic GMP-dependent mechanisms.
    Ignarro LJ; Byrns RE; Trinh K; Sisodia M; Buga GM
    Nitric Oxide; 2002 Sep; 7(2):75-82. PubMed ID: 12223176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nebivolol: endothelium-mediated vasodilating effect.
    Ritter JM
    J Cardiovasc Pharmacol; 2001 Dec; 38 Suppl 3():S13-6. PubMed ID: 11811387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
    Enseleit F; Hürlimann D; Lüscher TF
    J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.
    Lüscher TF; Yang Z
    Drugs; 1993; 46 Suppl 2():121-32. PubMed ID: 7512465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of ACE inhibitors and calcium antagonists: a logical approach.
    Ruschitzka FT; Noll G; Lüscher TF
    J Cardiovasc Pharmacol; 1998; 31 Suppl 2():S5-16. PubMed ID: 9605596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
    Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
    Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production.
    Broeders MA; Doevendans PA; Bekkers BC; Bronsaer R; van Gorsel E; Heemskerk JW; Egbrink MG; van Breda E; Reneman RS; van Der Zee R
    Circulation; 2000 Aug; 102(6):677-84. PubMed ID: 10931809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats.
    Oelze M; Daiber A; Brandes RP; Hortmann M; Wenzel P; Hink U; Schulz E; Mollnau H; von Sandersleben A; Kleschyov AL; Mülsch A; Li H; Förstermann U; Münzel T
    Hypertension; 2006 Oct; 48(4):677-84. PubMed ID: 16940222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Beta-1-Receptor Blocker Nebivolol Elicits Dilation of Cerebral Arteries by Reducing Smooth Muscle [Ca2+]i.
    Cseplo P; Vamos Z; Ivic I; Torok O; Toth A; Koller A
    PLoS One; 2016; 11(10):e0164010. PubMed ID: 27716772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney.
    Kakoki M; Hirata Y; Hayakawa H; Nishimatsu H; Suzuki Y; Nagata D; Suzuki E; Kikuchi K; Nagano T; Omata M
    Hypertension; 1999 Jan; 33(1 Pt 2):467-71. PubMed ID: 9931149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells.
    Mollnau H; Schulz E; Daiber A; Baldus S; Oelze M; August M; Wendt M; Walter U; Geiger C; Agrawal R; Kleschyov AL; Meinertz T; Münzel T
    Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):615-21. PubMed ID: 12692005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol.
    Kuroedov A; Cosentino F; Lüscher TF
    Cardiovasc Drug Rev; 2004; 22(3):155-68. PubMed ID: 15492765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation.
    Weiss R
    Vasc Health Risk Manag; 2006; 2(3):303-8. PubMed ID: 17326335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide mechanisms of nebivolol.
    Maffei A; Lembo G
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelium-dependent effects of converting-enzyme inhibitors.
    Vanhoutte PM; Boulanger CM; Illiano SC; Nagao T; Vidal M; Mombouli JV
    J Cardiovasc Pharmacol; 1993; 22 Suppl 5():S10-6. PubMed ID: 7508046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Endothelial mechanisms in vasomotor effects of ACE inhibitors].
    Busse R; Hecker M
    Z Kardiol; 1994; 83 Suppl 4():1-6. PubMed ID: 7856274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
    Ignarro LJ
    Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.